EMA Authorised: Kauliv (teriparatide) — Strides Pharma (Cyprus) Limited

View source ↗

Summary

The EMA has authorized Kauliv, a teriparatide-containing medicine by Strides Pharma (Cyprus) Limited, for osteoporosis and postmenopausal osteoporosis.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Osteoporosis
• Osteoporosis Postmenopausal

Drugs mentioned

• Kauliv (teriparatide)

Snippet

Status: Authorised. Therapeutic area: Osteoporosis;Osteoporosis, Postmenopausal. MAH: Strides Pharma (Cyprus) Limited. Decision date: 22/11/2024